newsfilter
← Latest News
Business Wire·

Simulations Plus Supported Development of Every FDA-Approved Drug in 2024

SLP's technology and expertise accelerates drug development and supports critical advancements in global healthcare Simulations Plus, Inc. (NASDAQ:SLP) ("Simulations Plus"), a leading provider of cheminformatics,